Telix Pharmaceuticals’ expansion phase shows no sign of running out yet, with the Australian radiopharma company paying $45 ...

As it works to build a 775-acre research campus in the Florida heat, the Moffitt Cancer Center is looking to cool things down ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Investors clearly appreciate the song that Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...